March 22nd 2024
In an interview with Targeted Oncology, Julie Chang, MD, discussed the minimal residual disease-adapted study in patients with previously untreated mantle cell lymphoma and the key findings from the trial.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Partially Halts Phase I Study of ACTR707 in Non-Hodgkin Lymphoma
March 12th 2020The FDA has placed a partial clinical hold on the phase I trial of ACTR707 in combination with rituximab in patients with relapsed/refractory B-cell lymphoma from Unum Therapeutics, following the submission of a safety report from the company. The FDA notified Unum of the hold verbally on March 4. Unum Therapeutics acknowledged the partial clinical hold in filings with the Securities and Exchange commission.
Read More
Cirmtuzumab/Ibrutinib Combo Achieves 50% CR Rate in R/R MCL Cohort
March 12th 2020Cirmtuzumab in combination with ibrutinib induced a clinical benefit rate of 100% in a small cohort of patients with relapsed or refractory mantle cell lymphoma, according to interim results of the phase I/II CIRLL trial.
Read More
Despite Benefits of Stem Cell Transplant in MCL, Best Practices Remain Elusive
March 4th 2020Both autologous stem cell transplant and allogeneic stem cell transplant can be used as consolidation therapy in patients with mantle cell lymphoma, according to results from a single-center analysis, presented in a poster at the 2020 Transplantation & Cellular Therapy Meetings. However, the benefit of alloSCT is offset by an increased risk of transplant-related mortality and the development of graft-versus-host-disease.
Read More
Careful Data Review Recommended for Upfront Treatment Selection in iNHL
February 29th 2020To enhance outcomes for patients with indolent non-Hodgkin lymphoma, an in-depth review of the available data is required. As a start, Sonali M. Smith, MD, University of Chicago Medicine, reviewed the clinical trial findings that are currently informing treatment selection in the frontline iNHL paradigm, at 24th Annual International Congress on Hematologic Malignancies.
Read More
Bendamustine Plus Rituximab Demonstrates Efficacy as Induction Therapy in MCL
February 26th 2020In an interview with Targeted Oncology at the 2019 ASH Annual Meeting, Diego Villa, MD, MPH, discussed the benefit of bendamustine plus rituximab versus R-CHOP in transplant-eligible and -ineligible patients with mantle cell lymphoma.
Read More
Real-World Analysis Explores Current Role of Acalabrutinib in MCL
February 25th 2020In an interview with Targeted Oncology, Kellie Ryan, MPH, discussed the data on how physicians are currently using acalabrutinib as treatment of patients with mantle cell lymphoma in the real-world setting. She highlighted where she sees this research evolving in time.
Read More
Evaluation of an expansion cohort of the pivotal phase I/II ZUMA-1 trial in patients with refractory large B-cell lymphoma revealed that early steroid intervention may have a positive impact on the toxicity profile of chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel, according to findings presented during a poster session at the 2020 Transplantation & Cellular Therapy Meetings in Orlando, Florida.
Read More
FDA Grants Priority Review to BLA for KTE-X19 in Relapsed/Refractory MCL
February 10th 2020A Biologics License Application for the investigational chimeric antigen receptor T-cell therapy agent, KTE-X19, was accepted by the FDA and granted Priority Review for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, according to a press release from Kite, developer of KTE-X19.<sup> </sup>
Read More
High Dose Cyclophosphamide Activity in MCL Is Similar to Other Bcell NHLs
January 16th 2020Salvage therapy with high‐dose cyclophosphamide showed meaningful clinical activity in a cohort of 6 patients with mantle cell lymphoma who were previously treated with ≥2 prior lines of therapy and had no other available options. These patients made up 14% of the 42 participants in a phase II study showing similar efficacy in adult patients with other relapsed or refractory B‐cell non‐Hodgkin lymphomas.
Read More
Ibrutinib Improves Responses Over Chemotherapy in R/R Mantle Cell Lymphoma
January 10th 2020In an interview with Targeted Oncology, Simon Rule, MD, discussed the findings from a pooled analysis evaluating the efficacy and safety of using ibrutinib in patients with relapsed/refractory mantle cell lymphoma. He also highlighted other abstracts of interest that were presented during the 2019 American Society of Hematology Annual Meeting that were of interest in the field of mantle cell lymphoma.
Read More
Flinn Examines Improved Response Rates with KTE-X19 in Mantle Cell Lymphoma
December 23rd 2019In an interview with Targeted Oncology, Ian W. Flinn, MD, PhD, discussed the results from the ZUMA-2 trial which evaluated the efficacy and safety of KTE-X19, a CAR T-cell therapy, in patients with relapsed/refractory mantle cell lymphoma. He highlighted how unique this product is compared to other CAR T-cell therapies and where he believes it will fit into the treatment landscape for patients with mantle cell lymphoma.
Read More
Long-Term Data Support Rituximab Maintenance After R-CHOP in Older Patients With MCL
December 21st 2019Older patients with mantle cell lymphoma were more likely to have a maintained response with induction rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone followed by rituximab maintenance when compared against R-CHOP and interferon-alpha maintenance.
Read More
Venetoclax Plus Ibrutinib Combo Shows Potential in Relapsed/Refractory MCL
December 17th 2019Andre Goy, MD, discusses the results from a small clinical trial, which was presented at the 2019 American Society of Hematology Annual Meeting that he found particularly significant for the treatment of patients with relapsed/refractory mantle cell lymphoma.
Watch
Hematology Experts Review Impactful Data from 2019 ASH Annual Meeting
December 13th 2019Following the 2019 ASH Annual Meeting, Targeted Oncology spoke with experts from various specialties in hematology. The experts highlighted some of the top abstracts from the meeting that will impact the way multiple myeloma, leukemias, MPNs, and lymphomas are treated.
Read More
BLA Submitted to FDA for KTE-X19 as Treatment of Relapsed/Refractory MCL
December 12th 2019A Biologics License Application for the investigational chimeric antigen receptor T-cell therapy agent, KTE-X19 has been submitted to the FDA for the treatment of adult patients with relapsed/refractory mantle cell lymphoma, according to a press release from Kite.<br />
Read More
FDA Submission for KTE-X19 Planned After High CR Rates Were Observed in MCL
December 10th 2019Patients with relapsed/refractory mantle cell lymphoma experienced a 67% complete remission rate and an objective response rate of 93% after treatment with the anti-CD19 CAR T-cell therapy KTE-X19, according to findings from the phase II ZUMA-2 study presented at the 2019 American Society of Hematology ASH Annual Meeting.
Read More
Ibrutinib May Lead to Late PFS Plateau in R/R Mantle Cell Lymphoma
December 9th 2019A prospective trial showed that treatment with ibrutinib might prompt a decrease in progression-free survival in patients with relapsed or refractory mantle cell lymphoma, according to long-term follow-up data presented at the 2019 American Society for Hematology Annual Meeting and Exposition.
Read More
Bendamustine/Rituximab as Induction Therapy in MCL
December 9th 2019<br /> Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, The University of British Columbia, discusses a retrospective analysis evaluating bendamustine and rituximab as induction therapy in both transplant eligible and ineligible patients with mantle cell lymphoma. <br />
Watch
A Look Back at FDA News from November 2019
December 2nd 2019In November 2019, the FDA approved a number of treatments, including acalabrutinib for the treatment of chronic lymphocytic leukemia and small lymphocytic leukemia, as well as zanubrutinib for the treatment of mantle cell lymphoma. A biosimilar for pegfilgrastim was also approved under indications.
Read More
Analysis Identifies Potential Targets for Older Patients With Mantle Cell Lymphoma
November 22nd 2019In an interview with <em>Targeted Oncology</em>, Lalit Sehgal, PhD, discussed the rationale for investigating how the tumor microenvironment impacts survival in patients with mantle cell lymphoma through various signaling pathways.
Read More
Long-term S1106 Trial Data Support Rituximab-Bendamustine Combo in Pre-Transplant MCL
November 21st 2019Five-year outcomes data from the S1106 phase II trial in patients with newly diagnosed mantle cell lymphoma found that the RB regimen was equally effective but less toxic than the RH regimen. <br />
Read More
BTK Inhibitors Continue to Improve the MCL Treatment Landscape
October 29th 2019In an interview with Targeted Oncology, Jia Ruan, MD, PhD, examined the evolving treatment landscape for mantle cell lymphoma. She also discussed modern strategies like precision medicine and ctDNA liquid biopsy that are aiding the evolution.
Read More
Rule Discusses the Potential of Zanubrutinib in the Treatment of Mantle Cell Lymphoma
October 28th 2019Simon Rule, MD, PhD, shares his thoughts on the FDA’s decision to grant zanubrutinib, a BTK inhibitor, priority review for the treatment of patients with mantle cell lymphoma. Should the drug be approved, it will be available for patients with MCL who have received at least 1 prior line of therapy.
Watch
KMT2D Mutations Emerge as Negative Biomarker in MCL Based on MIPI-Genetic Prognostic Score
October 23rd 2019Target resequencing and DNA profiling of purified tumor samples collected from younger patients with mantle cell lymphoma found that mutations of <em>KMT2D</em> and disruption of <em>TP53</em> by deletion or mutation were associated with an increased risk of progression and death, both in univariate and multivariate analysis, from standard treatments, according to a study published recently in <em>Haematologica</em>.<br />
Read More
Phase I/II Study of Cirmtuzumab/Ibrutinib Expands to Include MCL
October 21st 2019The phase I/II CIRLL trial has opened an expansion cohort to include patients with mantle cell lymphoma in the study of the monoclonal antibody, cirmtuzumab, plus ibrutinib. The study was previously open to patients with chronic lymphocytic leukemia and small lymphocytic leukemia only.<sup>1 </sup>
Read More